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BACE1 gene variants do not influence BACE1









The BACE1 gene encodes the beta-site APP-cleaving enzyme 1 and has been associated with Alzheimer’s disease
(AD). BACE1 is the most important b-secretase responsible for the generation of Alzheimer-associated amyloid b-
proteins (Ab) and may play a role in the amyloidogenic process in AD. We hypothesized that BACE1 gene variants
might influence BACE1 activity or other markers for APP metabolism in the cerebrospinal fluid (CSF) and thereby
contribute to the development of AD. We genotyped a Swedish sample of 269 AD patients for the rs638405 single
nucleotide polymorphism (SNP) in the BACE1 gene and correlated genotype data to a broad range of amyloid-
related biomarkers in CSF, including BACE1 activity, levels of Ab40,A b42, a- and b-cleaved soluble APP (a-sAPP and
b-sAPP), as well as markers for Alzheimer-type axonal degeneration, i.e., total-tau and phospho-tau181. Gene variants
of BACE1 were neither associated with amyloid-related biomarkers, nor with markers for axonal degeneration in AD.
Findings
Cleavage of the amyloid precursor protein (APP) by b-
and g-secretase gives rise to the amyloid b-protein (Ab)
found in senile plaques (SP) in Alzheimer’s disease
(AD). The BACE1 gene encodes the beta-site APP-cleav-
ing enzyme 1 (OMIM 604252), which is involved in b-
secretase activity [1-4]. The BACE1 gene is associated
with AD [5,6] and the BACE1 activity is elevated both
in brain tissue and in CSF in AD [7,8]. We hypothesized
that BACE1 gene variants might influence the BACE1
activity or other amyloid-related biomarkers related to
amyloid in the cerebrospinal fluid (CSF) and thereby
contribute to developing AD. We tested a single nucleo-
tide polymorphism (SNP) in the BACE1 gene to evaluate
the genetic influence on BACE1 activity, levels of Ab40,
Ab42, a-a n db-cleaved soluble APP (a-sAPP and b-
sAPP) in CSF from AD patients. Further we assessed
the BACE1 genetic influence on markers for Alzheimer-
type axonal degeneration (total-tau and phospho-tau181).
T h er s 6 3 8 4 0 5S N Ph a v eah i g ha l l e l ef r e q u e n c yw i t ha
global frequency of the least common variant of 0.32.
To our knowledge this is the first study investigates
BACE1 genotype data in relation to BACE1 activity and
other amyloid-related biomarkers in CSF from AD
patients.
We studied a Swedish Caucasian sample of 269 AD
patients (90 men and 179 women, mean age 74.7 ± 6.3
years) where CSF levels of total-tau, phospho-tau181 and
Ab42 were known. We measured the BACE1 activity,
levels of a-sAPP, b-sAPP and Ab40 in CSF samples
from 84 of the patients. All participants were recruited
at the Memory Clinic at the Malmö University Hospital.
The patients gave informed consent to participate in the
study, which was conducted according to the provisions
of the Helsinki Declaration a n da p p r o v e db yt h el o c a l
ethic committee. The diagnosis of “probable AD” was
made according to the NINCDS-ADRDA criteria [9].
No AD patient had any of the known familial forms of
autosomal dominant AD.
CSF samples were taken by lumbar puncture. BACE1
activity was determined with a sensitive and specific
solution-based assay previously described [10]. Levels of
total-tau, phospho-tau181 and Ab42 were measured using
established ELISA methods [11,12] while a-sAPP,
b-sAPP and Ab40 were quantified using MSD immu-
noassays (Cat#: K11120E and K111FTE), (Meso Scale
Discovery, Gaithersburg, MD, USA).
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standard methods. BACE1 alleles were determined using
the Dynamic Allele Specific Hybridization (DASH) tech-
nique as described earlier [13]. Optimal assay condi-
tions: 1.5 mM MgCl2,2 0 0μMd N T P s ,0 . 0 5U / μlT a q
polymerase, 0.15 pmol/μl forward biotinylated primer
(5′-Biotin-ATCCGGCGGGAGTGGTATTATG-3′), 0.75
pmol/μl reverse primer (5′-GTCCATTGATCTC-
CACCCGCAC-3′) (Invitrogen, Life Technologies) and 5-
20 ng DNA, 1xPCR buffer in a final volume of 25 μl.
The cycling profile was: 5 min 95°C, 40 cycles: 30 sec
95°C, 45 sec 60°C, 1 min 72°C and a final step of 10
min 72°C. To identify BACE1 alleles the probes 5′-
CACAATGATCACCTCATAA-3′ and 5′-CACAAT-
GATGACCTCATAA-3′ were used.
APOE genotyping was performed using minisequen-
cing as described before [14]. Gene designations follow
the recommendations of HUGO Gene Nomenclature
Committee [15].
The genotype and allele frequencies of the BACE1
rs638405 and APOE ε4 are shown in table 1. The analy-
sis of variance (ANOVA) was used to analyze the effects
of BACE1 genetic variants on MMSE, BACE1 activity
and CSF protein levels. To test the effects of known risk
factors, e.g., age, sex and APOE ε4 we identified signifi-
cantly relevant covariates for each outcome variable
(MMSE and levels of AD CSF biomarkers) using for-
ward stepwise linear regression. Hardy-Weinberg equili-
brium was assessed by c
2 statistics. The criterion for
significance was set at p < 0.05 for all statistical tests.
Statistical analyses were performed with the SYSTAT11
(SYSTAT Software GmbH, Erkrath, Germany) software.
We studied BACE1 gene variants in relation to BACE1
activity and levels of amyloid-related biomarkers in CSF
from AD patients. In the linear regression analysis we
found APOE ε4 to significantly interact with phospho-
tau18, Ab42 and MMSE. Subsequently, APOE ε4 was
included as covariate in the statistic model. We found
no effect of BACE1 gene variants on BACE1 activity or
levels of Ab40,A b42, a-sAPP and b-sAPP (Table 2). We
compared CSF levels of markers for axonal degeneration
(total-tau and phospho-tau181) between BACE1 gene
variants and found no significant differences in protein
levels (Table 2). The BACE1 SNP showed no association
with MMSE (data not shown).
The APOE allele distribution followed the expected
frequencies seen in AD populations (Table 1). Genotype
frequencies conformed to Hardy-Weinberg equilibrium
in AD patients.
We hypothesized that BACE1 gene variants might influ-
ence BACE1 activity or levels of amyloid-related biomar-
kers in the cerebrospinal fluid (CSF) and thereby
contribute to the development of AD. A genome-wide
screen of AD families has shown linkage to marker close to
BACE1 [16] and the rs638405 SNP has been tested in a
number of studies [5,17]. Other studies have found associa-
tion between the BACE1 gene and AD [5,18]. Even though
this SNP does not change the protein sequence it still can
have functional effects based on earlier findings where
BACE1 influenced levels of Ab in CSF [6]. We tested if the
rs2069456 SNP was associated with BACE1 activity or with
levels of Ab40,A b42, a-sAPP and b-sAPP in CSF from AD
patients. Further we assessed the influence on total-tau and
phospho-tau181.G e n ev a r i a n t so fBACE1 were neither
associated with amyloid-related biomarkers nor with mar-
kers for axonal degeneration. Our results do not support
that variants of the BACE1 gene affects BACE1 activity or
CSF levels of APP or Ab isoforms in AD.
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Table 1 BACE1 and APOE genotype and allele frequencies
in AD patients
BACE1
Genotype frequencies CC CG GG
AD (269) 50 (0.19) 117 (0.43) 102 (0.38)
Allele frequencies C G
AD (538) 217 (0.40) 321 (0.60)
APOE
Genotype frequencies No ε4 One ε4 Two ε4
AD (269) 74 (0.28) 135 (0.50) 60 (0.22)
Allele frequencies ε2/ε3 ε4
AD (538) 283 (0.53) 255 (0.47)
Abbreviations: Alzheimer’s disease (AD). Number of total genotypes and
alleles are given (N). Percentage of total is shown for the genotypes and
alleles respectively.
Table 2 BACE1 activity and biochemical markers in CSF
and BACE1 genotypes in AD patients
BACE1 genetic variants
CSF protein CC CG GG p-
value
Total-tau (pg/ml) 628.8 ± 38.7 612.7 ± 29.3 610.0 ± 33.4 0.699
Phospho-tau181
(pg/ml)
79.7 ± 3.9 73.8 ± 2.8 77.7 ± 3.4 0.506
Ab42 (pg/ml) 408.7 ± 11.8 419.4 ± 9.2 408.3 ± 9.9 0.575







BACE1 (pM) 29.2 ± 2.5 31.8 ± 2.0 33.6 ± 3.3 0.765
a-sAPP (ng/ml) 645.8 ± 77.0 660.5 ± 40.6 620.5 ± 41.8 0.962
b-sAPP (ng/ml) 393.3 ± 37.8 408.0 ± 24.9 399.6 ± 22.6 0.965
Abbreviations: Alzheimer’s disease (AD). Mean values (± SEM) are shown.
Adjusted p-values are shown for respective comparison.
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